MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

AbbVie Inc

Geschlossen

BrancheGesundheitswesen

189.23 -1.23

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

188.52

Max

191.99

Schlüsselkennzahlen

By Trading Economics

Einkommen

1.3B

1.3B

Verkäufe

-1.8B

13B

KGV

Branchendurchschnitt

81.846

39.857

EPS

2.46

Dividendenrendite

3.53

Gewinnspanne

9.66

Angestellte

55,000

EBITDA

3.2B

3.7B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+10.83% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.53%

2.42%

Nächstes Ergebnis

31. Juli 2025

Nächste Dividendenausschüttung

15. Aug. 2025

Nächstes Ex-Dividendendatum

14. Okt. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-5B

338B

Vorheriger Eröffnungskurs

190.46

Vorheriger Schlusskurs

189.23

Nachrichtenstimmung

By Acuity

24%

76%

51 / 376 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

AbbVie Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

30. Juni 2025, 13:02 UTC

Akquisitionen, Fusionen, Übernahmen

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion in Cash

25. Apr. 2025, 13:57 UTC

Ergebnisse

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised -- Update

25. Apr. 2025, 12:52 UTC

Ergebnisse

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised

9. Apr. 2025, 18:18 UTC

Wichtige Markttreiber

Pharma Shares Reverse Losses After Tariff Pause

9. Apr. 2025, 09:39 UTC

Wichtige Markttreiber

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

30. Juni 2025, 12:47 UTC

Akquisitionen, Fusionen, Übernahmen

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1B in Cash

30. Juni 2025, 12:33 UTC

Akquisitionen, Fusionen, Übernahmen

AbbVie Will Acquire Capstan, Including CPTX2309, a Potential First-In-Class in Vivo tLNP anti-CD19 CAR-T Therapy Candidate >ABBV

30. Juni 2025, 12:33 UTC

Akquisitionen, Fusionen, Übernahmen

AbbVie : Proposed Acquisition Strengthens Commitment to Transforming Patient Care With Capstan's Innovative tLNP Platform Technology >ABBV

30. Juni 2025, 12:32 UTC

Akquisitionen, Fusionen, Übernahmen

AbbVie Will Pay Up to $2.1B in Cash at Closing to Acquire Capstan >ABBV

30. Juni 2025, 12:31 UTC

Akquisitionen, Fusionen, Übernahmen

AbbVie To Acquire Capstan Therapeutics, Further Strengthening Commitment To Transforming Patient Care In Immunology >ABBV

7. Mai 2025, 09:30 UTC

Top News

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

28. Apr. 2025, 12:44 UTC

Ergebnisse

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

28. Apr. 2025, 09:33 UTC

Ergebnisse

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25. Apr. 2025, 16:03 UTC

Ergebnisse

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25. Apr. 2025, 14:00 UTC

Top News
Ergebnisse

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25. Apr. 2025, 12:24 UTC

Top News
Ergebnisse

AbbVie Stock Jumps as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25. Apr. 2025, 12:03 UTC

Top News
Ergebnisse

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25. Apr. 2025, 11:43 UTC

Ergebnisse

AbbVie 1Q U.S. HUMIRA Rev $744M >ABBV

25. Apr. 2025, 11:43 UTC

Ergebnisse

AbbVie 1Q International HUMIRA Rev $377M >ABBV

25. Apr. 2025, 11:43 UTC

Ergebnisse

AbbVie 1Q Global Skyrizi Rev $3.43B >ABBV

25. Apr. 2025, 11:43 UTC

Ergebnisse

AbbVie 1Q Net $1.29B >ABBV

25. Apr. 2025, 11:43 UTC

Ergebnisse

AbbVie 1Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

25. Apr. 2025, 11:43 UTC

Ergebnisse

AbbVie 1Q Global IMBRUVICA Rev $738M >ABBV

25. Apr. 2025, 11:43 UTC

Ergebnisse

AbbVie 1Q EPS 72c >ABBV

25. Apr. 2025, 11:43 UTC

Ergebnisse

AbbVie 1Q Adj EPS $2.46 >ABBV

25. Apr. 2025, 11:43 UTC

Ergebnisse

AbbVie 1Q Rev $13.34B >ABBV

25. Apr. 2025, 11:43 UTC

Ergebnisse

AbbVie Sees FY Adj EPS $12.09-Adj EPS $12.29 >ABBV

14. März 2025, 09:30 UTC

Top News

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

3. März 2025, 15:04 UTC

Akquisitionen, Fusionen, Übernahmen

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. -- IBD

28. Feb. 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

Peer-Vergleich

Kursveränderung

AbbVie Inc Prognose

Kursziel

By TipRanks

10.83% Vorteil

12-Monats-Prognose

Durchschnitt 212.13 USD  10.83%

Hoch 250 USD

Tief 170 USD

Basierend auf 18 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für AbbVie Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

18 ratings

12

Buy

6

Halten

0

Sell

Technischer Score

By Trading Central

180.37 / 195.54Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

51 / 376 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.